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An NQO1 Variant Affects Breast Cancer Prognosis
and Treatment Response
After radiation and surgery, women with early-stage breast
cancer are often given adjuvant therapy containing an an-
thracycline. Because these chemotherapeutic agents can
have serious side effects—including heart damage and an
increased risk of leukemia—and don’t have beneﬁcial
effects in a signiﬁcant proportion of women, researchers
have been searching for factors that could predict the
utility of anthracycline adjuvant therapy in individual
women. Fagerholm et al. report that a common missense
mutation in NQO1 is predictive of reduced survival in
women with breast cancer and is strongly associated with
a defective response to anthracyclines. NQO1 encodes
the NAD(P)H:quinone oxidoreductase 1, which is involved
in protection against oxidative stress and has a role in p53
stabilization. The missense change in this gene is associ-
ated with a complete deﬁciency for NQO1 activity, and
especially among women who have breast cancer and are
treated with anthracycline adjuvant therapy, those homo-
zygous for the NQO1 mutation have reduced rates of sur-
vival of breast cancer. Experiments in cell culture support
the idea that NQO1 activity inﬂuences the responsiveness
of cancer cells to anthracyclines and that these effects are
mediated by p53. The NQO1 genotype is also prognostic
in the setting of metastasis; in women with metastatic
breast cancer, none of the women homozygous for the
NQO1 mutation survived more than 26.7 months after
the detection of ametastasis, whereas 51% of womenwith-
out this genotype survived to this point. The potential im-
portance of this genetic variation in the setting of breast
cancer prognosis and treatment decisions is evidenced by
the fact that 4% of people of European descent and 20%
of those of Asian descent are homozygous for this missense
change.
Fagerholm et al. (2008). Nature Genetics. Published online
May 30, 2008. 10.1038/ng.155.
Transgenic Nonhuman Primate Model
of Huntington Disease
Researchers have gotten very adept at generating animal
models of human genetic disease, and these models have
substantially increased our understanding of many dis-1Department of Human Genetics, Emory University School of Medicine, Atla
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a ﬂy model truly reﬂects the human disease process. Non-
human primate models of these diseases might circumvent
some of these issues because of their relatedness to
humans, so the report by Yang et al. of a transgenic nonhu-
man primatemodel of Huntington disease (HD) is an excit-
ing advance. Their rhesus macaque model was generated
through insertion of exon 1 of the human HTT gene;
this is the portion of the gene containing the disease-asso-
ciated CAG repeat. To date, there have been ﬁve live-born
macaques expressing the transgene. Three of them had
multiple copies of the transgene and died within a month
of birth, although not before developing evidence of
movement dysfunction. Histopathological evidence of
Htt aggregation and the formation of inclusions in the
brain and other tissues were also evident. Of the remaining
two macaques, who are now more than six months old,
each expresses a single copy of the transgene, albeit with
different CAG repeat lengths. The ﬁrst has a normal CAG
repeat length of 29 and shows no signs of movement dys-
function, whereas the second has a pathogenic CAG repeat
length of 83 and showed evidence of dystonia and chorea
within a week of his birth. Although these studies are in
their infancy, Yang et al. have pushed the door open to
new and more closely linked models of human disease.
Yang et al. (2008). Nature. Published online May 18,
2008.10.1038/nature06975.
A Role for ARMS2 in AMD
Age-related macular degeneration (AMD) has been one of
the great success stories for genetic-association studies of
complex traits. Two chromosomal loci, 1q31 and 10q26,
are major genetic contributors to the development of this
disorder, which in developed countries is the leading cause
of visual impairment in the elderly. Surrounding the chro-
mosome 10q26 locus is a large block of linkage disequilib-
rium that includes two plausible candidate genes, HTRA1
and ARMS2. Which of these genes actually contributes to
AMD has been a matter of debate. Fritsche et al. argue
that ARMS2might be the relevant gene for AMD. They dis-
covered that a deletion-insertion polymorphism in the 30
untranslated region of ARMS2 removes a polyadenylation
signal and inserts an AU-rich element. These changes de-
stabilize transcripts expressed from this allele and lead tonta, GA 30322, USA
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reductions in the amount of ARMS2 protein that is ex-
pressed. In fact, homozygosity for the risk allele obviates
detectable ARMS2 protein expression in placental tissue.
The instability of ARMS2 transcripts encoded by the dele-
tion-insertion allele implicates the loss of ARMS2 function
as a potential key to the development of AMD in some peo-
ple, but although ARMS2 colocalizes with mitochondria in
the rods and cones of the photoreceptor, its exact function
remains unclear. Because the ARMS2 risk allele is found at
a frequency of 19% in a control population, a functional
role for ARMS2 in the development of AMD would mean
this allele could have a substantial contribution to AMD
in a general population.
Fritsche et al. (2008). Nature Genetics. Published online
May 30, 2008. 10.1038/ng.170.
miR-10a Enhances Ribosomal Protein Translation
MicroRNAs (miRNAs) are small RNAs that posttranscrip-
tionally regulate gene expression. Most microRNAs
(miRNAs) that have been studied bind to the 30 untrans-
lated region (UTR) of their target mRNAs and repress their
translation. On both counts, miR-10a seems to be an ex-
ception to this rule; it binds to the 50 UTR of its targets
and enhances their expression. Many of miR-10a’s targets
are mRNAs for ribosomal proteins. These RNAs contain
a TOP motif that provides the RNAs with a level of transla-
tional regulation that is environmentally sensitive. Under
starvation conditions, the TOP motif usually induces
translational repression of the mRNAs. However, miR-10a
binds just downstream of the TOP motif and counteracts
this effect, so the repression is relieved. At least under cer-
tain conditions, miR-10a thus increases expression of the
ribosomal proteins and stimulates ribosomal biogenesis.
As a result, global protein synthesis increases, and this
increased synthesis in turn seems to promote cells to un-
dergo transformation in vitro. This work opens the door
to studies of a new system of regulation by miRNAs; this4 The American Journal of Human Genetics 83, 3–4, July 2008system isn’t unique to miR-10a but is shared by other
members of the miR-10 family and so may be relevant in
many cell and tissue types in the body.
Orom et al. (2008). Molecular Cell 30, 460–471. 10.1016/
j.molcel.2008.05.001.
Is ASK the Answer to ALS?
Mutations in SOD1 are the most common known cause of
familial amyotrophic lateral sclerosis (ALS), a disease char-
acterized by the selective loss of motor neurons. Although
we know that SOD1 encodes the Cu/Zn-superoxide dismu-
tase and that these mutations cause the death of motor
neurons, it doesn’t appear that these effects are due to
a loss of SOD1 enzymatic activity. It is also not clear how
mutations in this widely expressed enzyme cause a disease
with such cell speciﬁcity. In trying to tease apart the mech-
anism of neuronal cell death, Nishitoh et al. discovered
that SOD1 mutations inhibit endoplasmic-reticulum-asso-
ciated degradation (ERAD) and trigger ER stress. These ef-
fects occur as a result of a Derlin-1—a component of the
ERAD machinery—interaction that is speciﬁc to mutant
forms of SOD1. The interaction with Derlin-1 triggers the
ASK1-dependent apoptosis pathway and thereby induces
cell death. In mice, the SOD1-Derlin-1 interaction is only
observed in liver and neuronal tissues, perhaps providing
a clue to the speciﬁcity of the pathogenic effects of SOD1
mutations. In support of a role for this pathway in SOD1-
mediated ALS, ASK1-deﬁcient neurons are more resistant
to cell death induced by SOD1 mutations. However, mice
that lack ASK1 are not protected from ALS, although their
mean time of survival is extended by 10%. Clearly, this
pathway is not the full story behind ALS, but it does pro-
vide hints to a mechanistic link between SOD1 mutations
and motor-neuron cell death.
Nishitoh et al. (2008). Genes and Development 22, 1451–
1464.
